372 related articles for article (PubMed ID: 22278418)
1. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Chen G; Xu S; Renko K; Derwahl M
J Clin Endocrinol Metab; 2012 Apr; 97(4):E510-20. PubMed ID: 22278418
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
3. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells.
Zheng X; Cui D; Xu S; Brabant G; Derwahl M
Int J Oncol; 2010 Aug; 37(2):307-15. PubMed ID: 20596658
[TBL] [Abstract][Full Text] [Related]
5. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative action of metformin in human lung cancer cell lines.
Ashinuma H; Takiguchi Y; Kitazono S; Kitazono-Saitoh M; Kitamura A; Chiba T; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Iwama A; Yokosuka O; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):8-14. PubMed ID: 22576795
[TBL] [Abstract][Full Text] [Related]
7. 1,25 dihydroxyvitamin D3 inhibits the proliferation of thyroid cancer stem-like cells via cell cycle arrest.
Peng W; Wang K; Zheng R; Derwahl M
Endocr Res; 2016 May; 41(2):71-80. PubMed ID: 27030645
[TBL] [Abstract][Full Text] [Related]
8. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
10. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang CY; Sneh G; Yu MA; Pardo FS; Aguilera J; Ongkeko WM
Laryngoscope; 2008 Aug; 118(8):1372-6. PubMed ID: 18475209
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
14. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
15. Metformin Suppresses Self-Renewal Ability and Tumorigenicity of Osteosarcoma Stem Cells via Reactive Oxygen Species-Mediated Apoptosis and Autophagy.
Zhao B; Luo J; Wang Y; Zhou L; Che J; Wang F; Peng S; Zhang G; Shang P
Oxid Med Cell Longev; 2019; 2019():9290728. PubMed ID: 31827709
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
17. Metformin targets gastric cancer stem cells.
Courtois S; Durán RV; Giraud J; Sifré E; Izotte J; Mégraud F; Lehours P; Varon C; Bessède E
Eur J Cancer; 2017 Oct; 84():193-201. PubMed ID: 28822889
[TBL] [Abstract][Full Text] [Related]
18. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
19. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
Stassi G; Todaro M; Zerilli M; Ricci-Vitiani L; Di Liberto D; Patti M; Florena A; Di Gaudio F; Di Gesù G; De Maria R
Cancer Res; 2003 Oct; 63(20):6784-90. PubMed ID: 14583474
[TBL] [Abstract][Full Text] [Related]
20. Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
Rotondi M; Coperchini F; Pignatti P; Magri F; Chiovato L
J Clin Endocrinol Metab; 2015 Mar; 100(3):E427-32. PubMed ID: 25590211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
